MAP2K7 and melanoma: Recent research in melanoma treatment has focused on combination immunotherapies (95), optimal sequencing and combination of BRAF-MEK and immune checkpoint inhibitors, understanding the mechanisms of primary and acquired resistance to these therapies, and biomarkers for treatment selection and monitoring (96).